Efficacy and Safety of Teriflunomide in Chinese Patients with Relapsing Forms of Multiple Sclerosis: A Subgroup Analysis of the Phase 3 TOWER Study

Efficacy and Safety of Teriflunomide in Chinese Patients with Relapsing Forms of Multiple Sclerosis: A Subgroup Analysis of the Phase 3 TOWER Study

Background: Disease-modifying therapy is the standard treatment for patients with multiple sclerosis (MS) in remission. The primary objective of the current analysis was to assess the efficacy and safety of two teriflunomide doses (7 mg and 14 mg) in the subgroup of Chinese patients with relapsing M...

Full description

Bibliographic Details
Main Authors: Wei Qiu, De-Hui Huang, Shi-Fang Hou, Mei-Ni Zhang, Tao Jin, Hui-Qing Dong, Hua Peng, Chao-Dong Zhang, Gang Zhao, Yi-Ning Huang, Dong Zhou, Wei-Ping Wu, Bao-Jun Wang, Ji-Mei Li, Xing-Hu Zhang, Yan Cheng, Hai-Feng Li, Ling Li, Chuan-Zhen Lu, Xu Zhang, Bi-Tao Bu, Wan-Li Dong, Dong-Sheng Fan, Xue-Qiang Hu, Xian-Hao Xu, for the TOWER Trial Chinese Group
Format: Article
Language:English
Published: Wolters Kluwer 2018-01-01
Series:Chinese Medical Journal
Subjects:
Chinese Patients; Efficacy; Phase 3; Relapsing Multiple Sclerosis; Safety; Teriflunomide; TOWER
Online Access:http://www.cmj.org/article.asp?issn=0366-6999;year=2018;volume=131;issue=23;spage=2776;epage=2784;aulast=Qiu

Internet

http://www.cmj.org/article.asp?issn=0366-6999;year=2018;volume=131;issue=23;spage=2776;epage=2784;aulast=Qiu

Similar Items